A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT06999187
This study is recruiting at 10 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Triple Negative Breast Cancer
- HER2-negative Breast Cancer
- Non Small Cell Lung Cancer
- Cervical Cancer
- Castrate Resistant Prostate Cancer
- Pancreatic Ductal Adenocarcinoma
- Head-and-neck Squamous Cell Carcinoma
- Endometrial Cancer
- Ovarian Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Urothelial Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Dren Bio
- Last updated on ClinicalTrials.gov
- January 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Dren Investigational Site · Denver, CO
Florida · 2
- Dren Investigational Site · Orlando, FL
- Dren Investigational Site · Sarasota, FL
North Carolina · 1
- Dren Investigational Site · Huntersville, NC
Oklahoma · 1
- Dren Investigational Site · Oklahoma City, OK
South Carolina · 1
- Dren Investigational Site · Greenville, SC
Texas · 3
- Dren Investigational Site · Austin, TX
- Dren Investigational Site · Dallas, TX
- Dren Investigational Site · San Antonio, TX
Virginia · 1
- Dren Investigational Site · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.